First-of-its-kind 1,000-patient clinical study will use RNA-based stool and saliva tests to detect colon polyps — early warning signs of colorectal cancer — before they become cancerous. Study aims to enhance colorectal cancer prevention by identifying polyp molecular signals, offering improved sensitivity over at-home DNA tests, which have limited ability to detect precancerous lesions. BELLEVUE, Wash. and LA JOLLA, Calif., July 14, 2025 /PRNewswire/ -- Viome Life Sciences, the leader in AI-po

Egret Therapeutics, a portfolio company of Turret Capital Management, is a clinical stage biotechnology company focused on function preservation following acute injuries NEW YORK, July 14, 2025 /PRNewswire/ -- Egret Therapeutics today announced the appointment of Dr. Geoffrey Ling, MD, PhD, to its Scientific Advisory Board (SAB). Dr. Ling, a renowned neurologist, Johns Hopkins professor, and former founding director of DARPA's Biological Technologies Office, joins Egret as the company intensifie

GOTHENBURG, Sweden, July 14, 2025 /PRNewswire/ -- Zinzino has initiated a process to acquire 35% of Xion International Group in order to form a joint venture to produce algae using bioreactors. The expanded collaboration is another strategically important step in Zinzino's growth plans, which focus on improving personal health and well-being on a global scale with innovative biotechnology and a pioneering product portfolio marketed through direct sales. Xion is an innovative, proprietary produ

Company also announces new 500-patient SUMMIT RISE study at the Society of NeuroInterventional Surgery annual meetingSAN MATEO, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced results from an independent, real-world study evaluating reperfusion outcomes following use of Route 92 Medical’s HiPoint® Reperfusion System, the first and onl

SINGAPORE, July 14, 2025 (GLOBE NEWSWIRE) -- Gero, an AI-driven biotechnology company focused on developing therapeutics for age-related diseases, today announced the appointment of Brian Kennedy, Ph.D., to its Board of Directors. Dr. Kennedy is a globally recognized leader in aging biology and translational longevity research. Dr. Kennedy is currently a Distinguished Professor in the Departments of Biochemistry and Physiology at the Yong Loo Lin School of Medicine, National University of S

First and only medicine approved by Health Canada for patients as young as 6-months of age with HoFH, an ultrarare, inherited form of high cholesterolTORONTO, July 14, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, today announced that Health Canada has extended the approval of Evkeeza® (evinacumab) as an adjunct to diet and other lo

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC and BOSTON and EMERYVILLE, Calif., July 14, 2025 /PRNewswire/ -- ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the "Business Combination Agreement") with XenoTherapeutics, Inc. ("Xeno"), a non-profit biotechnology company, under which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of ESSA (the "Common Shares"). XOMA Royalty Corporation

New “Decision to grant” communications in Canada and Israel For the treatment of aggression and social withdrawal MADRID and CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that it has received “Decision to grant” communications from the Canadian Intellectual Property Office and the Israel Patent Office for its patent applications CA30718

– Institute of Human Genetics at Heidelberg University Hospital ongoing EEG biomarker study on 15q13.3 CNVs – – Collaboration aims to uncover novel insights into the brain’s functional architecture in rare genetic conditions – – Building and growing a license business is an increasingly important pillar of Firefly’s commercial strategy – KENMORE, N.Y., July 14, 2025 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”)

61% Response Rate Observed in Third-Line or Earlier Patients SAN CARLOS, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that a real-world, retrospective study demonstrates the benefit of commercial Amtagvi® (lifileucel) in real-world clinical settings for patients w